Literature DB >> 16240209

A prospective study of gastric acid analysis and esophageal acid exposure in patients with gastroesophageal reflux refractory to medical therapy.

Sushil K Ahlawat1, Raja Mohi-Ud-Din, Dionne C Williams, Kathleen A Maher, Stanley B Benjamin.   

Abstract

A number of factors have been proposed to account for the lack of response to medical therapy in patients with gastroesophageal reflux; however, no controlled studies are available in the literature. The goal of this study was to determine possible causes of medical refractoriness in patients with gastroesophageal reflux. Gastric acid output and esophageal acid exposure were measured in patients who continue to have reflux symptoms despite aggressive antisecretory therapy. In addition, an upper endoscopy was also performed in each patient. Patients with a drug-controlled acid output < 1 mEq/hr and a supine total esophageal pH < 4 for less than 1.7% of the time measured were considered responsive to therapy; on the other hand, those with a drug-controlled gastric acid output > 1 mEq/hr and a supine esophageal pH < 4 for more than 1.7% of the time measured were considered resistant to therapy. Twenty-four patients met the inclusion criteria (13 male and 11 female; mean age, 52). Drug-controlled gastric acid output was more than 1 mEq/hr in 25% of patients and less than 1 mEq/hr in the remainder. Of those patients with a gastric acid output of less than 1 mEq/hr (18 patients), 8(44%) had a supine esophageal pH < 4 for more than 1.7% of the time, suggesting that factors other than gastroesophageal reflux likely contributed to their reflux-like symptoms. Acid suppression appears adequate in the majority of patients with gastroesophageal reflux refractory to medical therapy. The exact cause of persistent reflux-like symptoms in patients who fail medical treatment is uncertain but may be related to non-acid-related factors such as esophageal hypersensitivity to physiologic reflux, increased intake of air resulting in aerophagia, or other factors such as bile reflux.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16240209     DOI: 10.1007/s10620-005-3001-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

Review 2.  Functional esophageal disorders.

Authors:  R E Clouse; J E Richter; R C Heading; J Janssens; J A Wilson
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

3.  Comorbidity of aerophagia in GERD patients: outcome of laparoscopic antireflux surgery.

Authors:  T Kamolz; T Bammer; F A Granderath; R Pointner
Journal:  Scand J Gastroenterol       Date:  2002-02       Impact factor: 2.423

4.  Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized.

Authors:  W K Kauer; J H Peters; T R DeMeester; A P Ireland; C G Bremner; J A Hagen
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

Review 5.  Chest pain as a consequence of abnormal visceral nociception.

Authors:  R O Cannon; S B Benjamin
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

6.  Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.

Authors:  L P Leite; B T Johnston; R J Just; D O Castell
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

7.  Gastric acid hypersecretion in refractory gastroesophageal reflux disease.

Authors:  M J Collen; J H Lewis; S B Benjamin
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

8.  Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial.

Authors:  R E Clouse; P J Lustman; T C Eckert; D M Ferney; L S Griffith
Journal:  Gastroenterology       Date:  1987-04       Impact factor: 22.682

9.  Role of intragastric and intraoesophageal alkalinisation in the genesis of complications in Barrett's columnar lined lower oesophagus.

Authors:  S E Attwood; C S Ball; A P Barlow; L Jenkinson; T L Norris; A Watson
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

10.  Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus.

Authors:  G Champion; J E Richter; M F Vaezi; S Singh; R Alexander
Journal:  Gastroenterology       Date:  1994-09       Impact factor: 22.682

View more
  2 in total

Review 1.  Impact of changing epidemiology of gastroesophageal reflux disease on its diagnosis and treatment.

Authors:  Hugo Bonatti; Sami R Achem; Ronald A Hinder
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

2.  Effects of Platycodin D on Reflux Esophagitis due to Modulation of Antioxidant Defense Systems.

Authors:  Su-Yeon Cho; Chang-Hyun Song; Ji-Eun Lee; Seong Hun Choi; Sae-Kwang Ku; Soo-Jin Park
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-26       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.